Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 8/20 | 0.74 |
| ▸ | BLM | P54132 | 2/20 | 0.74 |
| ▸ | HBB | P68871 | 2/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | EDNRA | P25101 | 1/20 | 0.74 |
| ▸ | HTR2A | P28223 | 1/20 | 0.74 |
| ▸ | RECQL | P46063 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | VCP | P55072 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | POLG | P54098 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370760 | 0.89 | PNP (0.87) | PNPBLMHBBUSP2TSHR | |
| SCHEMBL1767748 | 0.86 | PNP (0.74) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL3664893 | 0.85 | PNP (1.00) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL2269160 | 0.85 | PNP (1.00) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL3175 | 0.85 | PNP (1.00) | PNPBLMHBBUSP2TSHR | |
| SCHEMBL572050 | 0.85 | PNP (0.81) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL19031784 | 0.84 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL16060281 | 0.84 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL16061083 | 0.84 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| SCHEMBL10421280 | 0.84 | PNP (0.79) | PNPBLMHBBUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2851368-B1 | COMPLEX COMPOUNDS OF GERMANIUM, METHODS FOR PRODUCING SAME, AND DRUGS | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU WDS FARMA (RU) | 2019-01-02 | — | — | EP | claimed |
| EP-2852592-A1 | A PROCESS FOR THE PREPARATION OF VALACYCLOVIR HYDROCHLORIDE | Piramal Enterprises Limited (IN) | 2015-04-01 | — | — | EP | claimed |
| WO-2013076688-A1 | A PROCESS FOR THE PREPARATION OF VALACYCLOVIR HYDROCHLORIDE | Piramal Enterprises Limited (IN) | 2013-05-30 | — | — | WO | claimed |
| EP-0596542-B1 | Therapeutic nucleosides | WELLCOME FOUND (GB) | 1996-05-29 | — | — | EP | claimed |
| EP-0596542-A1 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-05-11 | — | — | EP | claimed |
| US-5061708-A | TREATMENT OF INFECTION BY HERPES OR CYTOMEGALO VIRUS | BURROUGHS WELLCOME CO. (US) | 1991-10-29 | — | — | US | claimed |
| JP-3115284-A | — | — | None | — | — | JP | disclosed |
| EP-2852592-A1 | A PROCESS FOR THE PREPARATION OF VALACYCLOVIR HYDROCHLORIDE | Piramal Enterprises Limited (IN) | 2015-04-01 | — | — | EP | disclosed |
| CN-101708338-B | Prodrug containing sterides structures and high dispersion preparation thereof | INST OF RADIATION & RADICALIZATION MEDICINE THE ACADEMY OF MILITARY MEDICAL SCIENCES | 2014-06-04 | — | — | CN | disclosed |
| WO-2013076688-A1 | A PROCESS FOR THE PREPARATION OF VALACYCLOVIR HYDROCHLORIDE | Piramal Enterprises Limited (IN) | 2013-05-30 | — | — | WO | disclosed |
| CN-101708338-A | Prodrug containing sterides structures and high dispersion preparation thereof | INST OF RADIATION & RADICALIZA | 2010-05-19 | — | — | CN | disclosed |
| US-20070112193-A1 | VALACYCLOVIR PROCESS | DR. REDDY'S LABORATORIES, INC. | 2007-05-17 | — | — | US | disclosed |
| WO-2006035452-A1 | NOVEL PSEUDOMORPH OF VALACICLOVIR HYDROCHLORIDE | MATRIX LABORATORIES LTD (IN) | 2006-04-06 | — | — | WO | disclosed |
| EP-0596542-B1 | Therapeutic nucleosides | WELLCOME FOUND (GB) | 1996-05-29 | — | — | EP | disclosed |
| EP-0308065-B1 | Therapeutic nucleosides | WELLCOME FOUND (GB) | 1995-01-04 | — | — | EP | disclosed |
| EP-0596542-A1 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-05-11 | — | — | EP | disclosed |
| US-5061708-A | TREATMENT OF INFECTION BY HERPES OR CYTOMEGALO VIRUS | BURROUGHS WELLCOME CO. (US) | 1991-10-29 | — | — | US | disclosed |
| JP-H03115284-A | NUCLEOTIDE FOR MEDICAL TREATMENT | WELLCOME FOUND LTD:THE | 1991-05-16 | — | — | JP | disclosed |
| EP-0308065-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112193-A1 | VALACYCLOVIR PROCESS | TYMP, UMPS, PNP | PNP 3/4885BLM 1781/4885HBB 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.